Last reviewed · How we verify
NCT03948724: EDHITO
Impact of Therapeutic Patient Education on the Toxicity of Immune Checkpoint Inhibitors in Oncology
NA trial testing Therapeutic education program in Therapeutic Patient Education in 411 participants. Completed in 22 August 2024.
4 August 2023
Quick facts
| Lead sponsor | Institut Cancerologie de l'Ouest |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | prevention |
| Enrollment | 411 |
| Start date | 11 December 2019 |
| Primary completion | 4 August 2023 |
| Estimated completion | 22 August 2024 |
| Sites | 9 locations across France |
Drugs / interventions tested
- Therapeutic education program
- Usual Information
Conditions studied
- Therapeutic Patient Education — all drugs for Therapeutic Patient Education →
- Immune Checkpoint Inhibitors — all drugs for Immune Checkpoint Inhibitors →
- Melanoma — all drugs for Melanoma →
- Advanced Non-small Cell Lung Cancer — all drugs for Advanced Non-small Cell Lung Cancer →
Sponsor
Institut Cancerologie de l'Ouest — full company profile →
Who can join
18 and older, any sex, with Therapeutic Patient Education or Immune Checkpoint Inhibitors. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The aim of this therapeutic education program is to reduce the apparition of immune-related Adverse Event with patients treated with ICI
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT03948724
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Institut Cancerologie de l'Ouest trials
Trials by the same sponsor.
- NCT06978296 — HIghly MetAstatic Life Prolonging Therapy-Resistant Prostate Cancer: Role of Stereotactic Radiotherapy for Bone and Lymp · NA · not yet recruiting
- NCT06967987 — Study Evaluating the Combination of Bemarituzumab + FLOT Chemotherapy in Perioperative Setting for Resectable Stage cT2- · Phase 2 · withdrawn
- NCT06756802 — Reproductive Health in Breast Cancer Survivor · active not recruiting
- NCT07007325 — Prospective Feasibility Pilot Study Evaluating the Value of [68Ga]Ga-PENTIXAFOR PET-CT in Patients With Metastatic Small · EARLY_PHASE1 · not yet recruiting
- NCT06994702 — Impact of the MRI Restraint System on the Quality of the Synthetic Scan for Intracranial Radiotherapy Treatment · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03948724 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Institut Cancerologie de l'Ouest
- Last refreshed: 17 August 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03948724.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing